anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
An acyloxyacyl hydrolase from the human promyelocyte cell line HL-60 has been found to specifically hydrolyze fatty acids from their ester linkages to hydroxy groups of 3-hydroxyfatty acids, the latter being being bound in turn to lipopolysaccharide glycosaminyl residues. The hydrolyzed fatty acids may include dodecanoic acid, tetradecanoic acid and hexadecanoic acid. This enzyme showed a molecular weight by gel exclusion chromatography between about 50,000 Daltons and about 70,000 Daltons, and a molecular weight by polyacrylamide gel electrophoresis with sodium dodecylsulphate, using reduced molecular weight standards, of approximately 54,000 to 60,000 Daltons. Altered bacterial lipopolysaccharide substantially without fatty acids bound in ester linkage to hydroxy groups of 3-hydroxyfatty acids covalently linked to a glucosaminyl moiety of lipopolysaccharide lipid A are produced. Since the structure of the lipid A moiety is highly conserved, acyloxyacyl hydrolase may act on lipopolysaccharide of many different pathogenic bacteria (for example Salmonella, Escherichia, Hemophilus, and Neisseria). Such altered bacterial lipopolysaccharide, having toxicity reduced more than immunostimulatory activity, may be therapeutically useful: (1) as vaccines to prevent Gram-negative bacterial diseases by inducing antibodies to lipopolysaccharide O-polysaccharide or R-core antigens, (2) as antidotes to treat or prevent Gram-negative bacterial sepsis (&#34;septic shock&#34;), or (3) as adjuvants to enhance formation of antibodies to other antigens. the acyloxyacyl hydrolase itself may be prophylactically or therapeutically useful to detoxify endogenous lipopolysaccharide in patients with Gram-negative bacterial diseases. The enzyme may also be used to remove toxic lipopolysaccharide from therapeutic injectants.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a skin aging inhibitor or improver having an excellent effect of inhibiting or improving the skin aging caused by ultraviolet rays, and to provide a cosmetic containing the same.  &lt;P&gt;SOLUTION: This skin aging inhibitor or improver contains (a) one, two or more kinds of extracts from plants containing isoflavone or its glycoside and (b) one, two or more kinds of extracts selected from a group comprising extracts from plants containing apigenin or its glycoside and/or plants containing procyanidin. The cosmetic contains the inhibitor or improver. An extract from soybeans, alfalfa leaves, red clover flowers, pueraria mirifica roots or white lupine seeds is exemplified as the extract from the plant containing the isoflavone or its glycoside. An extract from grapefruit seeds, perilla seeds or chamomile flowers is exemplified as the extract from the plant containing the apigenin or its glycoside. An extract from grape, apple, strawberry or cranberry fruits or seeds thereof is exemplified as the extract from the plant containing the procyanidin.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a water-in-oil type cosmetic which has excellent makeup retainability, has good skin compatibility, is freshly, has smooth spreadability, and has excellent temporal stability.  &lt;P&gt;SOLUTION: This water-in-oil type cosmetic is characterized by comprising the following components (A), (B) and (C), wherein the hydroxyl group value (OHV) of the component (A) is 10 to 150. The component (A) is one or more compounds selected from the group consisting of a ditrimethylolpropane fatty acid ester compound, a ditrimethylolpropane polybasic carboxylic acid polycondensation product, a polycondensation product of the ester compound with a polybasic carboxylic acid, and a polycondensation product of ditrimethylolpropane, a fatty acid and a polybasic carboxylic acid. The component (B) is a surfactant. The component (C) is an aqueous component.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide new complexes of major histocompatibility complex (MHC) molecules, and to provide uses of such complexes.  &lt;P&gt;SOLUTION: Provided are single chain MHC class II complexes that include a class II β2 chain modification, e.g. deletion of essentially the entire class II β2 chain. In another aspect, provided is single chain MHC class II which comprises an immunoglobin constant chain or fragment. Further, provided are polyspecific MHC complexes comprising at least one single chain MHC class II molecule. The MHC complexes are useful for a variety of applications including: (1) in vitro screens for identification and isolation of peptides that modulate activity of selected T cells, including peptides that are T cell receptor antagonists and partial agonists, and (2) methods for suppressing or inducing an immune response in a mammal.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
Systems and methods are provided for evaluating and correcting physical performance of an activity by a human. A user performing one or more physical activities may be evaluated based on criteria relating to their movement, such as strength and technique. The user&#39;s performance in relation to these criteria is then rated, and the values for the criteria are combined to provide an overall performance score. The performance score is used to determine a user&#39;s overall readiness and ability to perform the physical activity which was evaluated or an overall ability to perform physical activities. Performance scores for more than one physical activity may be combined to provide an overall performance ready score that captures the person&#39;s overall physical ability. Comparisons of performance scores over time may provide information as to whether a user is improving, and could be applied to evaluating physical rehabilitations from injuries.
Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand (&#39;TRAIL&#39;) Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds TR-2 from the animal. Antibodies reactive with TR-2 are provided. Also provided are cells producing antibodies reactive with TR-2, pharmaceutical compositions comprising antibodies reactive with TR-2, methods using antibodies reactive with TR-2, and kits comprising antibodies reactive with TR-2. Also provided are methods of decreasing or preventing binding of an antibody to TR-2 by administering such a polypeptide.
&lt;P&gt;PROBLEM TO BE SOLVED: To construct an in vitro experiment system for reproducing quinolinic acid elimination and transportation in a blood-brain barrier by elucidating quinolinic acid elimination mechanism in a central nerve system.  &lt;P&gt;SOLUTION: Transportation of quinolinic acid in the blood-brain barrier is evaluated by using a conditionally immortalized brain capillary endothelial cell. Consequently, existence of a transportation system for discharging quinolinic acid to the blood-brain barrier of the central nerve system is indicated. Discharge of quinolinic acid from the brain is evaluated by using the transportation system. Further, an evaluation system using TR-BBB13 cell being the conditionally immortalized brain capillary endothelial cell is excellent as a means for examining the influence of various compounds on uptake of quinolinic acid, newly provides an evaluation system useful for screening a medicine influencing discharge of quinolinic acid in the central nerve system and is extremely useful for developing a therapeutic agent for a central nerve disease in the blood-brain barrier.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
In an environment where it is beneficial for chronic health care patients to receive individualized attention on a daily basis, a health care network ( 10 ) is provided. Each patient receives a user interface device ( 12 ) such as a set top box for accessing the network ( 10 ). Based on the patient&#39;s health care history, a nurse or other health care professional interfaces with a server ( 22 ) and constructs a care plan specific to that patient by filling out appropriate sections of a care plan template. An itinerary arrangement processor ( 32 ) organizes content gleaned from the patient&#39;s care plan and constructs a serially arranged itinerary for the patient to experience each day. The patient logs on to the network ( 10 ) and is immediately presented with the day&#39;s itinerary, without having to navigate any menus. Resultantly, the patient will have an easier experience, and will not miss any material.
Prodn. of non-informational, pure polydesoxyribonucleotides (PDRN) having biological activities comprises (a) pulping the placenta of emochorial mammals; (b) thermal inactivation of endogenous desoxyribonucleases liberated during antolysis; (c) controlled proteolysis of the material; (d) sepn. of insoluble residue from the aq. phase; (e) sepn. of PDRN from the liq. by complexation with solid or liq. quat. bases or by salt formation with divalent metals; (f) purificn. of PDRN after decomplexation or elution with solns. of alkaline earth metal salt; and (g) controlled partial depurinisation of native PDRN in order to eliminate the informational capability (viruses, onogenes). The SO obtd. PDRN are claimed characterised by anticomplement activity in vitro; inhibition of chemical mediators of inflammation in vitro; inhibition of inflammation due to corragheenin or foreign bodies; inhibition of leucocyte migration in vivo; and therapeutic activity on &#34;cervico-vaginities, lesions, due to dithermocoagulation, extropion and transformations areas&#34; (Si2).
530,902. Phosphoric acid derivatives of aminobenzenesulphonamide salts. HOFFMANN-LA ROCHE &amp; CO., AKT.-GES., F. July 5, 1939, No. 19577. Convention date, July 29, 1938. [Class 2 (iii)] Compounds having a bactericidal action are prepared by neutralizing phosphoric acid derivatives of 4-amino-benzene sulphonamides with bases which contain at least four carbon atoms and one nitrogen atom and have at least one ring present, the nitrogen atom being either a constituent of a ring or in aliphatic combination or by reacting salts of phosphoric acid derivatives of 4-amino-benzene sulphonamides with salts of such bases. Bases mentioned include quinine, acriflavine or other quinoline and acridine bases. In examples: (1) An aqueous solution of quinine monohydrochloride is reacted with an aqueous solution of the sodium salt of sulphanilamide phosphamic acid to give the quinine salt of sulphanilamide phosphamic acid. (2) The same compound as obtained in example (1) is also obtained by treating an aqueous suspension of quinine with sulphanilamide phosphamic acid. (3) Moist hydroquinine base is neutralized with an aqueous solution of sulphanilamide phosphamic acid. (4) Tyramine hydrochloride and the sodium salt of sulphanilamide phosphamic acid are reacted in aqueous solution to effect salt formation. (5) Emetine base is reacted in an aqueous medium with sulphanilamide phosphamic acid to give the corresponding salt. (6) Hordenine sulphate and sulphanilamide phosphamic acid are reacted together to form the sulphanilamide phosphamate of hordenine.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a color-changing cosmetic exhibiting excellent coloring state and color-changing state and to provide a cosmeticizing method using the cosmetic.  &lt;P&gt;SOLUTION: The color-changing cosmetic comprises one or more kinds of coloring agents, one or more kinds of developers and one or more color-changing agents. In the color-changing cosmetic, coloring occurs by mutual action between the coloring agents and developers and the color-changing agent stably exists without reacting with the coloring agents or developers and does not cause color change in formulation, and the change of color occurs by mutual action between color-changing agents and developers when used. The color-changing cosmetic comprises a first preparation containing one or more kinds of coloring agents and one or more kinds of developers and a second preparation containing one or more kinds of color-changing agents and changes color by mixing the first preparation with the second preparation when used. The cosmeticizing method comprises using the color-changing cosmetic.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
Mineral and strong organic acid addition salts of tetracycline or chlortetracycline are prepared by dissolving the amphoteric antibiotic in methyl &#34;Cellosolve&#34; (Registered Trade Mark), and adding one equivalent of the acid dissolved in water.  Specified are salts with hydrochloric, hydrobromic, hydriodic, sulphuric and nitric acids.ALSO:A therapeutically effective composition useful for the preparation of intramuscularly injectable liquid preparations comprises a mixture of an acid addition salt of tetracycline or chlortetracycline (see Group IV (b)) and magnesium chloride.  It is preferred to use two molecules of magnesium chloride to one molecule of the antibiotic.  Specified acid addition salts are the hydrochloride, hydrobromide, hydroiodide, sulphate and nitrate. The injectable vehicle may be water, propylene glycol or oils such as sesame and peanut oils.  Optional ingredients for aqueous injections are (a) a non-toxic, water-soluble organic acid, e.g. citric, gluconic, lactic, ascorbic, maleic, malic, malonic and nicotinic acids, an hydroxy acid, or a compound which on addition of water forms such an acid, e.g. glucurono-lactone; and (b) a water-soluble local anaesthetic, e.g. procaine hydrochloride and other dialkylamino alkanol esters of p-aminobenzoic acid.
PURPOSE: Provided are a liposome base for the hair growth including the extract of a natural product as an active ingredient, a cosmetic composition for the hair growth containing the same, and a method for improving the absorption of components of the natural product using the same. Therefore, depilation preventing and hair growth promoting effects are improved. CONSTITUTION: A liposome base for the hair growth includes 0.0001-20 wt.% of the extract of a natural product selected from the group consisting of Thuja orientalis Linne, Paratenodera sinensis, Torilis japonica, Polygonum sachalinense Fr. et Schm., Broussonetia kazinoki, Morus alba Linne, licorice root, Lycium chinense Mill and job&#39;s tear. it further contains lecithin, ethanol, ester oil and propyleneglycol. A cosmetic composition for the hair growth contains 1-30 wt.% of the liposome base.
&lt;P&gt;PROBLEM TO BE SOLVED: To easily grasp the progress situation of each inspection.  &lt;P&gt;SOLUTION: A process managing part 2 manages the progress situation of each process performed in a process processing part 3 and allows a GUI display part 5 to display the progress situation and a progress situation management screen for performing the work of each process. The process managing part 2 manages contents of an operation performed on the progress situation management screen displayed in the GUI display part 5, and updates the display of the progress situation management screen according to the operation contents. The GUI display part 5 displays the progress situation management screen including a GUI operated by an operator for processing each process by the control of the process managing part 2. For example, the GUI display part 5 indicates one inspection as one icon, and arranges icons on the screen in the processing order of processes. The GUI display part 5 visually displays waiting situations on the icons arranged on the screen.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a health food and drink having higher immunopotentiative effects by using both of mature fruits and immature fruits belonging to the genus Malus, such as Malus domestica and Malus pumila, or fruits belonging to the genus Pyrus so that the natural immunity by natural killer cells, macrophages, and the like, and the activity of lymphocytes are increased.  &lt;P&gt;SOLUTION: This health food and drink is composed so as to administer both of mature fruits and immature fruits belonging to the genus Malus, such as Malus domestica and Malus pumila, or fruits belonging to the genus Pyrus. Thereby, it is clarified that the natural immunity by natural killer cells, macrophages, and the like, are increased so as not only to modulate cancerated cells but also to prevent canceration of non-cancerated cells. The health food and drink can be daily taken. As a result, cancerization is prevented and the preventing effect is increased.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a means for improving or preventing alopecia and sparse hair, particularly stress-related alopecia and sparse hair.  &lt;P&gt;SOLUTION: The hair growing material composed of extracts of the following crude medicines or the following components is added to an external preparation for skin, preferably a hair cosmetic. These crude medicines include Rosa roxburghii of the family Rosaceae, Foeniculum vulgare Mill. of the family Umbelliferae, Malva sylvestris L. of the family Malvaceae, Rose Fruit of the family Rosaceae, apricot of the family Rosaceae, whitethorn of the family Rosaceae, Citrus unshu Marc. of the family Rutaceae, Ophipogonis Tube of the family Liliaceae, loquat of the family Rosaceae, Ruscus aculeatus L. of the family Liliaceae, Artemisia princeps of the family Compositae, Sanguisorba officinalis L. of the family Rosaceae, Ononis spinosa L. of the family Leguminosae, seaweed, Simmondssia Chinensis, Citrus reticulata Blanco of the family Rutaceae, Salvia officinalis L. of the family Labiatae, Humulus lupulus L. of the family Moraceae, Plectranthus rugosus of the family Labiatae, Ligusticum wallichii Franch. of the family Umbelliferae. Rosa of the family Rosaceae, Ginkgo biloba L. of the family Ginkgoaceae, Eugenia aromatica of the family Myrtaceae or the like. These components include vitamin E nicotinate, an extract of pearl protein or the like.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
PURPOSE:To provide a fluidity improver which allows the fluidity of powder to be greatly improved and retained over a long period of time, consisting of fine silica powder made hydrophobic with a specified diorganosiloxane oligomer. CONSTITUTION:1-50pts.wt. diorganosiloxane oligomer of the formula (wherein R is a monovalent hydrocarbon group; n is 1-15; Q is halogen, hydroxyl or OR&lt;1&gt;; and R&lt;1&gt; is a monovalent hydrocarbon group) is added to 100pts.wt. fine silica powder having a very low water content (e.g., fumed silica). The mixture is mixed until a homogeneous mixture is formed. The mixture is heated at 100-200 deg.C to make the powder hydrophobic, thus obtaining a fluidity improver having such characteristics that its specific surface area (BET method) is 180+ or -100m&lt;2&gt;; its carbon content is 5+ or -3wt%; its apparent density is 75+ or -35g/l; its compression density is 220+ or -35mg/cm&lt;2&gt; when 1.5g of a sample is placed under a pressure of 3.4kg/cm&lt;2&gt; for 4min; and its silanol titer is 1.0+ or -1.0ml; the titer being expressed by the titer of an aq. soln. of 0.1N-NaOH required for changing the pH of a dispersion from 4.0-9.0. The dispersion obtd. by dispersing 2.0g of a sample in a liquid mixture of 25ml of ethanol and 75ml of a 20wt% aq. soln. of NaCl. 0.2-0.3wt% said fluidity improver is added to powder.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide new integumentary system tissue production-promoting technology, namely to provide a composition which has an integumentary system tissue production-promoting effect and is high in safety.  &lt;P&gt;SOLUTION: This integumentary system tissue production-promoting composition is characterized by comprising an ingredient originated from a plant in Ericacees, Ericaceae. The integumentary system tissue production-promoting composition has a trichogenous action, a hair papilla cell proliferation-promoting action, a hair cycle growth period-inducing action, a vasodilator action, a melamine production-promoting action, a tyrosinase synthesis-promoting action, and the like. It is highly possible that the integumentary system tissue production-promoting composition can continuously safely be used for a long period, because of being originated from a natural material. Therefore, the integumentary system tissue production-promoting composition can be applied to various medicines, foods (including feeds for animals), drinks, cosmetics, and the like.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
A method for treating pulmonary hypertension and other diseases involving a defect in collagen metabolism, by administration of an effective amount of a liposome encapsulated copolymer conjugate antifibrotic composition, is disclosed. The antifibrotic agent is preferably proline analogs, such as cis-4-hydroxy-L-proline (CHOP), 3,4-dehydro-DL-proline (DHP), (R)-(−)-2-thiazolidine-4-carboxylic acid (THP), and (S)-(−)-2-azetidinecarboxylic acid (ACA). Consistent, high loadings (&gt;90%) of the antifibrotic agent are achieved by first forming a dipeptide with L-lysine, after which the dipeptide is copolymerized with the polymer component to form the copolymer conjugate. The polymer is preferably poly(ethylene glycol) having a weight average molecular weight of from about 500 to about 15,000. Efficient delivery and consistent release of the antifibrotic agent inhibits collagen accumulation and treats the diseases involved. Accordingly, there is a substantial reduction in the quantity of antifibrotic agent necessary, and thus a corresponding reduction in the potential for toxicity that would otherwise result from its prolonged administration.
FIELD: medicine.SUBSTANCE: invention relates to the field of medicine, namely to cardiology. Myocardial perfusion is analyzed by volumetric computed tomography (VCT), with pharmacological breakdown of sodium adenosine triphosphate (ATP), which is performed in two stages. At the first stage, the examination is carried out at rest with introduction of a contrast agent. At the second stage - not less than 20 minutes after the first introduction of the contrast preparation, the study is carried out in a stress state which is induced by infusion through a peripheral venous catheter of 1 % ATP solution at rate of 0.10–0.20 mg/kg in minute for 1–5 minutes. At the same time from the beginning of infusion of ATP or when the criteria for stopping the pharmacological test, such as the occurrence of retrosternal pains and/or ischemic ECG dynamics, without interrupting the infusion, 60–90 mg of a non-ionic iodine-containing contrast preparation with concentration of 350–370 mg of iodine/ml is introduced intravenously bolus at rate of 4–5 ml/s. At the same time at the first and second stages prior to the introduction of the contrast preparation, a natural examination is carried out, all stages of the VCT are necessarily performed with prospective synchronization with the ECG in the diastole phase, where the trigger is set for 65–93 % of the cardiac cycle phase. ECG electrodes are applied so that they are outside the field of the projection of the heart with the possibility of excluding artefacts from them in the left ventricular myocardial perfusion assessment zone. At the second stage, additional blood pressure control is performed, and as a result of the VCT, tomographs are taken without artifacts from LV motion, which characterize at least one phase of the cardiac cycle, at least 360 sections. Weakening of the myocardial density (MD) is determined on the basis of which the following values are calculated: a contrast index (CI) as a relation of myocardial infarction on the entire section to an MD of the subendocardial segment with reduced contrast enhancement. That is followed by determining the myocardial perfusion reserve (MPR), which is calculated as the ratio of infrared rest to infrared load. If the MPR value ≤ 0.7 is the presence of left ventricular myocardial ischemia.EFFECT: method enables diagnosing left ventricular myocardial ischemia with varying degrees of coronary artery changes, avoiding multiple-stage examination of patients, more accurate diagnosis verification for the purpose of timely drug-induced intervention and improved patient&#39;s prognosis.1 cl, 4 dwg, 3 ex